


**Product Name** : AZD4604  
**Cat. No.** : PC-72603  
**CAS No.** : 2241039-81-4  
**Molecular Formula** : C<sub>28</sub>H<sub>31</sub>F<sub>2</sub>N<sub>7</sub>O<sub>4</sub>S  
**Molecular Weight** : 599.658  
**Target** : JAK  
**Solubility** : 10 mM in DMSO



1. Magnus Nilsson, et al. *J Med Chem.* 2023 Sep 22. doi: 10.1021/acs.jmedchem.3c00554.

## Biological Activity

AZD4604 (Londamocitinib, AZD-4604) is a, potent, highly selective, ATP-competitive and oral **JAK1** inhibitor with IC<sub>50</sub> of 0.54 nM, shows >1000-fold selectivity over other JAK family members.

AZD4604 effectively inhibits the differentiation of Th1, Th2, and Th17 cells as indicated by a dose-dependent decrease in the production of Th-specific signature cytokines including reduction in IL-4, IL-5, and IL-13 productions by Th2 cells.

AZD4604 significantly blocks IL-4-induced STAT6 phosphorylation in CD4+ T cells.

AZD4604 blocks IL-13-induced STAT6 phosphorylation in monocytes with IC<sub>50</sub> of 28 nM.

AZD4604 shows anti-inflammatory effect.

## References

